Conférences  >  Sciences biologiques  >  Biotechnologie  >  États-Unis

CHI

Commercializing breakthrough immune-oncology therapeutics is becoming increasingly challenging due to funding limitations, high cost and attrition rates in the clinic, regulatory uncertainties, persistent therapeutic safety and efficacy concerns, and a general lack of understanding of basic biology guiding research in this space. As we develop the 2025 conference program, we are struck by the fact that, despite these challenges, there remains a strong desire to continue to find effective therapeutics for solid tumors. The 13th Annual Immuno-Oncology Summit showcases successes in preclinical and clinical studies grounded in a deep understanding of biology. Coverage spans solid tumor innovations, including bi/multispecific antibodies, antibody-drug conjugates (ADCs), allogenic and in vivo CAR-Ts, TILs, TCRs, Tregs, multiple cell therapies working together, the tumor microenvironment, innate immunity, gamma delta T cells, NK cells, organoid modeling, data science, and machine learning. The program also explores autoimmunity as a critical and complementary area of focus.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

Cancérologie,    Immunologie et Allergie

CHI

Join a global community of thought leaders and innovators shaping the future of bioprocessing. Dive into cutting-edge research, share insights with industry experts, and tackle the challenges of bioprocess R&D, scale-up, quality, and analytics.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

CHI

In its 23rd year Discovery on Target is the premier event highlighting “hot” drug targets and emerging modalities, technologies and strategies for pursuing those targets. The numerous conferences, symposia, courses and training seminars offer key insights for the successful discovery and development of novel therapeutics, from small molecules to biologics to chimeras and conjugates. The 4 day event covers innovations in target identification and lead generation, which includes cancer therapies, protein degradation, induced proximity, AI/machine learning, membrane proteins, translational models, synthetic biology and other relevant topics. New this year is an increased coverage of GLP-1, MASH and obesity, ADCs and bispecifics and on small molecules targeting DNA.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

Cancérologie,    Pharmacologie et développement des médicaments